Leverage • Blau Farmacêutica
BLAU3
Blau Farmaceutica is a multinational pharmaceutical company, a pioneer in biotechnology in Brazil and a strong institutional player. Its business model focuses on five specialties: oncology, hematology, infectious diseases, anesthesiology, and specialties. The company has a portfolio of highly complex drugs, including biologics, oncology, and antibiotics. Blau is present in several Latin American countries, such as Argentina, Colombia, Peru and Uruguay, and also in the United States. The hospital segment accounts for most of its net revenue.
—
N.D./EBITDA
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
26,6%
Debt/Equity
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!